By: Sara Radcliffe CLSA President & CEO CLSA – California Life Sciences Association July 20, 2016 Welcoming New Members Please welcome our newest CLSA members: Amaryllis, Nucleics, BioINK, Cepheus Biosciences, Inc., Igantia, Rex Animal Health, SeaSpine, SyntheX, and Veracyte, Inc.! These organizations join our 750+ membership portfolio to add significant expertise and resources to the CLSA network. … Continue reading CLSA Hosts CDC Director for Discussion on Pandemic Preparedness, Q&A with PaxVax CEO on Emerging Viruses; Welcoming New CLSA Members
In recent years, a new round of terrifying viruses has captured the public’s imagination. Ebola, H1N1, SARS, Zika and other pathogens strike rapidly, mutate without warning and pose a major threat to public health. We recently chatted with PaxVax CEO Nima Farzan about how we can better unite government and industry to prepare for these dangers.
Our President & CEO Sara Radcliffe provides an update on some of the other key happenings at CLSA.
Recently, the FDA announced the formation of the Patient Engagement Advisory Committee (PEAC) and requested public comments on what topics the committee should consider, which are due November 20th. FDA also published three requests for nominations to serve on the committee, including one for industry members which is due October 21st.
CLSA President & CEO Sara Radcliffe pens an op-ed in The Sacramento Bee regarding H.R. 9, federal legislation that would weaken the process that turns research into products, new companies.
CLSA President & CEO Sara Radcliffe discusses California’s leadership in life sciences in this San Diego Union-Tribune article.
CLSA issues a statement on appointing three new leaders from City of Hope National Medical Center, Hogan Lovells US LLP and UC Davis to their board during the 3rd quarter meeting of 2015.
On July 10, the House overwhelmingly approved the 21st Cures Act, a comprehensive legislative package to accelerate the pace of biomedical research and development in the U.S. CLSA President & CEO Sara Radcliffe comments on the passage of this landmark legislation.
CLSA’s President & CEO Sara Radliffe & CLSI Executive Director Lori Lindburg chat with Ron Leuty of the San Francisco Business Times regarding San Francisco’s preparation to host BIO 2016.
CLSA President & CEO Sara Radcliffe pens an exclusive op-ed in Roll Call applauding the 21st Century Cures Act. This landmark package of legislation includes a series of improvements to the healthcare system that will improve the lives of millions around the world, by accelerating the pace of drug, device and diagnostics discovery and development.